VTVT
vTv Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$25.17
−4.59%Oct 27, 2026, 12:00 UTC
vTv Therapeutics announced that the first participant was randomized in its Phase 2a Hybrid CATT1 pilot study evaluating cadisegliatin in people with type 1 diabetes who use hybrid closed-loop insulin delivery systems.
Source:Oct 7, 2026, 20:01 UTC
The FDA granted orphan drug designation to vTv Therapeutics Inc.’ HPPD for sickle cell disease.
Source:Oct 5, 2026, 12:00 UTC
vTv Therapeutics completed enrollment in its Phase 3 CATT1 study of Cadisegliatin in Type 1 Diabetes, with topline results expected in mid-2027.
Source:Aug 6, 2026, 12:00 UTC
vTv Therapeutics reported financial results for the second quarter ended June 30, 2026.
Source: